Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋（中国、日本、韓国、インド、東南アジア）
南アメリカ（ブラジル、アルゼンチン、コロンビアなど）
中東およびアフリカ（サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS INDUSTRY
2.1 Summary about Immune Thrombocytopenic Purpura Therapeutics Industry
2.2 Immune Thrombocytopenic Purpura Therapeutics Market Trends
2.2.1 Immune Thrombocytopenic Purpura Therapeutics Production & Consumption Trends
2.2.2 Immune Thrombocytopenic Purpura Therapeutics Demand Structure Trends
2.3 Immune Thrombocytopenic Purpura Therapeutics Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Eltrombopag Olamine
4.2.2 Fostamatinib Disodium
4.2.3 GL-2045
4.2.4 Avatrombopag
4.2.5 BI-655064
4.2.6 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Eltrombopag Olamine
5.2.2 Fostamatinib Disodium
5.2.3 GL-2045
5.2.4 Avatrombopag
5.2.5 BI-655064
5.2.6 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Eltrombopag Olamine
6.2.2 Fostamatinib Disodium
6.2.3 GL-2045
6.2.4 Avatrombopag
6.2.5 BI-655064
6.2.6 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Eltrombopag Olamine
7.2.2 Fostamatinib Disodium
7.2.3 GL-2045
7.2.4 Avatrombopag
7.2.5 BI-655064
7.2.6 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Eltrombopag Olamine
8.2.2 Fostamatinib Disodium
8.2.3 GL-2045
8.2.4 Avatrombopag
8.2.5 BI-655064
8.2.6 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Eltrombopag Olamine
9.2.2 Fostamatinib Disodium
9.2.3 GL-2045
9.2.4 Avatrombopag
9.2.5 BI-655064
9.2.6 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Amgen Inc.
10.1.2 Baxalta Incorporated
10.1.3 Boehringer Ingelheim GmbH
10.1.4 Bristol-Myers Squibb Company
10.1.5 Eisai
10.1.6 Hansa Medical AB
10.1.7 Immunomedics, Inc.
10.1.8 Intas Pharmaceuticals Ltd.
10.1.9 Jiangsu Hengrui Medicine Co., Ltd.
10.1.10 Merck & Co., Inc.
10.1.11 Momenta Pharmaceuticals, Inc.
10.1.12 Novartis AG
10.1.13 Pfizer Inc.
10.2 Immune Thrombocytopenic Purpura Therapeutics Sales Date of Major Players (2017-2020e)
10.2.1 Amgen Inc.
10.2.2 Baxalta Incorporated
10.2.3 Boehringer Ingelheim GmbH
10.2.4 Bristol-Myers Squibb Company
10.2.5 Eisai
10.2.6 Hansa Medical AB
10.2.7 Immunomedics, Inc.
10.2.8 Intas Pharmaceuticals Ltd.
10.2.9 Jiangsu Hengrui Medicine Co., Ltd.
10.2.10 Merck & Co., Inc.
10.2.11 Momenta Pharmaceuticals, Inc.
10.2.12 Novartis AG
10.2.13 Pfizer Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
